Literature DB >> 23889297

Expression of moesin and CD44 is associated with poor prognosis in gastric adenocarcinoma.

Woon Yong Jung1, Youngran Kang, Hyunjoo Lee, Young-Jae Mok, Han Kyeom Kim, Aeree Kim, Baek-Hui Kim.   

Abstract

AIMS: CD44 has been reported as a negative prognostic marker in gastric cancer. It interacts with moesin in epithelial-mesenchymal transition. To date, to our knowledge, there has been no clinical study dealing with the relationship between moesin and gastric adenocarcinoma. We analysed the expression of moesin and CD44 in gastric adenocarcinoma tissue, and correlations with clinicopathological factors. METHODS AND
RESULTS: A retrospective analysis was made of 430 patients who had undergone gastrectomy at the Korea University Guro Hospital between 2002 and 2005 for gastric adenocarcinoma. Using tissue microarray and immunohistochemical staining, moesin expression was observed in 192 (44.7%) cases; it was associated significantly with poorly differentiated histology, invasion depth, lymph node metastasis, lymphatic invasion and advanced pathological TNM stage. CD44 expression was not correlated with clinicopathological features or moesin expression. Moesin expression was a strong predictor of lymph node metastasis in logistic regression analysis. Both moesin expression and CD44 expression were associated significantly with poor overall survival in univariate analysis. Furthermore, in multivariate analysis, moesin and CD44 were independent markers of poor prognosis, along with pathological TNM stage and older patient age.
CONCLUSION: Moesin expression and CD44 expression might be useful markers of poor prognosis in gastric adenocarcinoma.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD44; adenocarcinoma; epithelial-mesenchymal transition; moesin; stomach

Mesh:

Substances:

Year:  2013        PMID: 23889297     DOI: 10.1111/his.12202

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.

Authors:  Prajna Paramita Naik; Subhadip Mukhopadhyay; Prashanta Kumar Panda; Niharika Sinha; Chandan Kanta Das; Rajakishore Mishra; Shankargouda Patil; Sujit Kumar Bhutia
Journal:  Cell Prolif       Date:  2017-11-23       Impact factor: 6.831

Review 2.  TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1.

Authors:  Breege V Howley; Philip H Howe
Journal:  Cytokine       Date:  2018-02-01       Impact factor: 3.861

Review 3.  Meta-Analysis of Prognostic and Clinical Significance of CD44v6 in Esophageal Cancer.

Authors:  Bangli Hu; Wei Luo; Rui-Ting Hu; You Zhou; Shan-Yu Qin; Hai-Xing Jiang
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

4.  Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer.

Authors:  Francisco Bárbara Abreu Barros; Agnes Assao; Natália Galvão Garcia; Suely Nonogaki; André Lopes Carvalho; Fernando Augusto Soares; Luiz Paulo Kowalski; Denise Tostes Oliveira
Journal:  BMC Cancer       Date:  2018-01-08       Impact factor: 4.430

5.  CD44 splice isoform switching determines breast cancer stem cell state.

Authors:  Honghong Zhang; Rhonda L Brown; Yong Wei; Pu Zhao; Sali Liu; Xuan Liu; Yu Deng; Xiaohui Hu; Jing Zhang; Xin D Gao; Yibin Kang; Arthur M Mercurio; Hira Lal Goel; Chonghui Cheng
Journal:  Genes Dev       Date:  2019-01-28       Impact factor: 11.361

6.  CD44, Sonic Hedgehog, and Gli1 Expression Are Prognostic Biomarkers in Gastric Cancer Patients after Radical Resection.

Authors:  Chen Jian-Hui; Zhai Er-Tao; Chen Si-Le; Wu Hui; Wu Kai-Ming; Zhang Xin-Hua; Chen Chuang-Qi; Cai Shi-Rong; He Yu-Long
Journal:  Gastroenterol Res Pract       Date:  2015-12-29       Impact factor: 2.260

Review 7.  Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved.

Authors:  Li Lu; Menglin Wu; Longhao Sun; Weidong Li; Weihua Fu; Xuening Zhang; Tong Liu
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.